A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)
Status:
Completed
Trial end date:
2013-07-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that treatment with odanacatib will
result in increased bone mineral density (BMD) compared to treatment with placebo. This study
will also evaluate the safety and efficacy of odanacatib for male osteoporosis participants.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Calcium Calcium Carbonate Cholecalciferol Vitamin D Vitamins